Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia

Investigators conducted a pilot clinical trial of a humanized CD19 CAR T-cell product in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia or B-lymphoblastic lymphoma, treated in two cohorts: with or without prior CAR exposure.